How much profit has MannKind made this year?
MannKind has made 20.37 M USD this year.
MannKind Net Income 2024
MannKind Net Income
20.37 M USD
Ticker
MNKD
ISIN
US56400P7069
WKN
A2DMZL
In 2024, MannKind's profit amounted to 20.37 M USD, a -270.62% increase from the -11.94 M USD profit recorded in the previous year.
The MannKind Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | 169.44 |
| 2027e | 136.11 |
| 2026e | 83.33 |
| 2025e | 48.15 |
| 2024e | 20.37 |
| 2023 | -11.94 |
| 2022 | -87.4 |
| 2021 | -80.9 |
| 2020 | -57.2 |
| 2019 | -51.9 |
| 2018 | -87 |
| 2017 | -117.3 |
| 2016 | 125.7 |
| 2015 | -368.4 |
| 2014 | -198.4 |
| 2013 | -191.5 |
| 2012 | -169.4 |
| 2011 | -160.8 |
| 2010 | -170.6 |
| 2009 | -220.1 |
| 2008 | -303 |
| 2007 | -293.2 |
| 2006 | -230.5 |
| 2005 | -114.3 |
| 2004 | -95.9 |
MannKind Revenue, EBIT, Net Income US56400P7069 · A2DMZL
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MannKind, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MannKind from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MannKind’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MannKind. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MannKind’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MannKind’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MannKind’s growth potential.
MannKind Revenue, EBIT and net profit per share
| Date | MannKind Revenue | MannKind EBIT | MannKind Net Income |
|---|---|---|---|
| 2029e | 522.3 M undefined | 0 undefined | 0 undefined |
| 2028e | 474.3 M undefined | 180.54 M undefined | 169.44 M undefined |
| 2027e | 421.32 M undefined | 164.67 M undefined | 136.11 M undefined |
| 2026e | 386.81 M undefined | 162.8 M undefined | 83.33 M undefined |
| 2025e | 330.11 M undefined | 101.52 M undefined | 48.15 M undefined |
| 2024e | 286.09 M undefined | 62.46 M undefined | 20.37 M undefined |
| 2023 | 198.96 M undefined | 15.19 M undefined | -11.94 M undefined |
| 2022 | 99.8 M undefined | -66.7 M undefined | -87.4 M undefined |
| 2021 | 75.4 M undefined | -51.3 M undefined | -80.9 M undefined |
| 2020 | 65.1 M undefined | -37.5 M undefined | -57.2 M undefined |
| 2019 | 63 M undefined | -46.5 M undefined | -51.9 M undefined |
| 2018 | 27.9 M undefined | -81.1 M undefined | -87 M undefined |
| 2017 | 11.7 M undefined | -94.6 M undefined | -117.3 M undefined |
| 2016 | 174.8 M undefined | 62.9 M undefined | 125.7 M undefined |
| 2015 | 0 undefined | -138.1 M undefined | -368.4 M undefined |
| 2014 | 0 undefined | -179.6 M undefined | -198.4 M undefined |
| 2013 | 0 undefined | -169.4 M undefined | -191.5 M undefined |
| 2012 | 0 undefined | -140.5 M undefined | -169.4 M undefined |
| 2011 | 100,000 undefined | -134.2 M undefined | -160.8 M undefined |
| 2010 | 100,000 undefined | -152.5 M undefined | -170.6 M undefined |
| 2009 | 0 undefined | -209.8 M undefined | -220.1 M undefined |
| 2008 | 0 undefined | -305.8 M undefined | -303 M undefined |
| 2007 | 0 undefined | -307.4 M undefined | -293.2 M undefined |
| 2006 | 100,000 undefined | -233.7 M undefined | -230.5 M undefined |
| 2005 | 0 undefined | -118.1 M undefined | -114.3 M undefined |
| 2004 | 0 undefined | -77.1 M undefined | -95.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -77.1 M USD | -95.9 M USD |
| 2005 | 0 USD | -118.1 M USD | -114.3 M USD |
| 2006 | 100,000 USD | -233.7 M USD | -230.5 M USD |
| 2007 | 0 USD | -307.4 M USD | -293.2 M USD |
| 2008 | 0 USD | -305.8 M USD | -303 M USD |
| 2009 | 0 USD | -209.8 M USD | -220.1 M USD |
| 2010 | 100,000 USD | -152.5 M USD | -170.6 M USD |
| 2011 | 100,000 USD | -134.2 M USD | -160.8 M USD |
| 2012 | 0 USD | -140.5 M USD | -169.4 M USD |
| 2013 | 0 USD | -169.4 M USD | -191.5 M USD |
| 2014 | 0 USD | -179.6 M USD | -198.4 M USD |
| 2015 | 0 USD | -138.1 M USD | -368.4 M USD |
| 2016 | 174.8 M USD | 62.9 M USD | 125.7 M USD |
| 2017 | 11.7 M USD | -94.6 M USD | -117.3 M USD |
| 2018 | 27.9 M USD | -81.1 M USD | -87 M USD |
| 2019 | 63 M USD | -46.5 M USD | -51.9 M USD |
| 2020 | 65.1 M USD | -37.5 M USD | -57.2 M USD |
| 2021 | 75.4 M USD | -51.3 M USD | -80.9 M USD |
| 2022 | 99.8 M USD | -66.7 M USD | -87.4 M USD |
| 2023 | 198.96 M USD | 15.19 M USD | -11.94 M USD |
| 2024e | 286.09 M USD | 62.46 M USD | 20.37 M USD |
| 2025e | 330.11 M USD | 101.52 M USD | 48.15 M USD |
| 2026e | 386.81 M USD | 162.8 M USD | 83.33 M USD |
| 2027e | 421.32 M USD | 164.67 M USD | 136.11 M USD |
| 2028e | 474.3 M USD | 180.54 M USD | 169.44 M USD |
| 2029e | 522.3 M USD | 0 USD | 0 USD |
MannKind stock margins US56400P7069 · A2DMZL
The MannKind margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MannKind. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MannKind.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MannKind's sales revenue. A higher gross margin percentage indicates that the MannKind retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MannKind's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MannKind's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MannKind's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MannKind. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MannKind's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MannKind Margin History
| MannKind Gross margin | MannKind Profit margin | MannKind EBIT margin | MannKind Profit margin |
|---|---|---|---|
| 2029e | 70.76 % | 0 % | 0 % |
| 2028e | 70.76 % | 38.06 % | 35.72 % |
| 2027e | 70.76 % | 39.08 % | 32.3 % |
| 2026e | 70.76 % | 42.09 % | 21.54 % |
| 2025e | 70.76 % | 30.75 % | 14.58 % |
| 2024e | 70.76 % | 21.83 % | 7.12 % |
| 2023 | 70.76 % | 7.64 % | -6 % |
| 2022 | 44.59 % | -66.83 % | -87.58 % |
| 2021 | 51.06 % | -68.04 % | -107.29 % |
| 2020 | 62.98 % | -57.6 % | -87.86 % |
| 2019 | 55.71 % | -73.81 % | -82.38 % |
| 2018 | 26.52 % | -290.68 % | -311.83 % |
| 2017 | -47.01 % | -808.55 % | -1,002.56 % |
| 2016 | 71.34 % | 35.98 % | 71.91 % |
| 2015 | 70.76 % | 0 % | 0 % |
| 2014 | 70.76 % | 0 % | 0 % |
| 2013 | 70.76 % | 0 % | 0 % |
| 2012 | 70.76 % | 0 % | 0 % |
| 2011 | 70.76 % | -134,200 % | -160,800 % |
| 2010 | 70.76 % | -152,500 % | -170,600 % |
| 2009 | 70.76 % | 0 % | 0 % |
| 2008 | 70.76 % | 0 % | 0 % |
| 2007 | 70.76 % | 0 % | 0 % |
| 2006 | 70.76 % | -233,700 % | -230,500 % |
| 2005 | 70.76 % | 0 % | 0 % |
| 2004 | 70.76 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 70.76 % | 0 % | 0 % |
| 2005 | 70.76 % | 0 % | 0 % |
| 2006 | 70.76 % | -233,700 % | -230,500 % |
| 2007 | 70.76 % | 0 % | 0 % |
| 2008 | 70.76 % | 0 % | 0 % |
| 2009 | 70.76 % | 0 % | 0 % |
| 2010 | 70.76 % | -152,500 % | -170,600 % |
| 2011 | 70.76 % | -134,200 % | -160,800 % |
| 2012 | 70.76 % | 0 % | 0 % |
| 2013 | 70.76 % | 0 % | 0 % |
| 2014 | 70.76 % | 0 % | 0 % |
| 2015 | 70.76 % | 0 % | 0 % |
| 2016 | 71.34 % | 35.98 % | 71.91 % |
| 2017 | -47.01 % | -808.55 % | -1,002.56 % |
| 2018 | 26.52 % | -290.68 % | -311.83 % |
| 2019 | 55.71 % | -73.81 % | -82.38 % |
| 2020 | 62.98 % | -57.6 % | -87.86 % |
| 2021 | 51.06 % | -68.04 % | -107.29 % |
| 2022 | 44.59 % | -66.83 % | -87.58 % |
| 2023 | 70.76 % | 7.64 % | -6 % |
| 2024e | 70.76 % | 21.83 % | 7.12 % |
| 2025e | 70.76 % | 30.75 % | 14.58 % |
| 2026e | 70.76 % | 42.09 % | 21.54 % |
| 2027e | 70.76 % | 39.08 % | 32.3 % |
| 2028e | 70.76 % | 38.06 % | 35.72 % |
| 2029e | 70.76 % | 0 % | 0 % |
MannKind Aktienanalyse
What does MannKind do?
MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding MannKind's Profit Margins
The profit margins of MannKind represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of MannKind's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating MannKind's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
MannKind's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When MannKind’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about MannKind stock
How has the profit developed compared to last year?
The profit has increased by -270.62% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does MannKind publish its earnings?
MannKind publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of MannKind?
The profits of MannKind are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of MannKind?
You can learn more about the earnings of MannKind by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does MannKind pay?
Over the past 12 months, MannKind paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MannKind is expected to pay a dividend of 0 USD.
What is the dividend yield of MannKind?
The current dividend yield of MannKind is .
When does MannKind pay dividends?
MannKind pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MannKind?
MannKind paid dividends every year for the past 0 years.
What is the dividend of MannKind?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MannKind located?
MannKind is assigned to the 'Health' sector.
Wann musste ich die Aktien von MannKind kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MannKind from 8/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did MannKind pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of MannKind in the year 2023?
In the year 2023, MannKind distributed 0 USD as dividends.
In which currency does MannKind pay out the dividend?
The dividends of MannKind are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MannKind stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MannKind
Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
